Vir Biotechnology, Inc.
VIR
$4.38
$0.020.46%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -75.91% | -73.79% | -13.90% | -33.82% | -83.93% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -75.91% | -73.79% | -13.90% | -33.82% | -83.93% |
| Cost of Revenue | 9.67% | -2.18% | -15.78% | -20.29% | -27.21% |
| Gross Profit | -27.61% | -10.82% | 16.11% | 17.16% | -179.70% |
| SG&A Expenses | -33.66% | -34.96% | -31.76% | -22.34% | -14.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.00% | -10.06% | -19.48% | -20.72% | -24.46% |
| Operating Income | -10.25% | 1.64% | 20.20% | 18.46% | -70.05% |
| Income Before Tax | -11.72% | -5.28% | 16.73% | 18.19% | -79.19% |
| Income Tax Expenses | 103.00% | 86.71% | 91.24% | 89.98% | 27.27% |
| Earnings from Continuing Operations | -13.91% | -7.08% | 15.14% | 11.22% | -84.35% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -100.00% | -100.00% |
| Net Income | -13.91% | -7.08% | 15.14% | 11.21% | -84.39% |
| EBIT | -10.25% | 1.64% | 20.20% | 18.46% | -70.05% |
| EBITDA | -11.85% | 0.76% | 20.05% | 18.81% | -72.09% |
| EPS Basic | -12.10% | -5.24% | 16.56% | 12.57% | -83.42% |
| Normalized Basic EPS | -16.48% | -1.11% | 22.76% | 26.11% | -73.74% |
| EPS Diluted | -11.97% | -5.12% | 16.64% | 12.47% | -81.70% |
| Normalized Diluted EPS | -16.48% | -1.11% | 22.76% | 26.11% | -71.12% |
| Average Basic Shares Outstanding | 1.66% | 1.66% | 1.58% | 1.44% | 1.29% |
| Average Diluted Shares Outstanding | 1.66% | 1.66% | 1.58% | 1.44% | 0.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |